NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 230 filers reported holding NEKTAR THERAPEUTICS in Q2 2022. The put-call ratio across all filers is 0.20 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $48,745 | -91.0% | 84,744 | -15.3% | 0.00% | -100.0% |
| Q1 2022 | $539,000 | +123.7% | 100,000 | +861.4% | 0.01% | +133.3% |
| Q2 2020 | $241,000 | -82.0% | 10,401 | -74.5% | 0.00% | -87.0% |
| Q4 2018 | $1,341,000 | +512.3% | 40,755 | +1036.2% | 0.02% | +1050.0% |
| Q3 2018 | $219,000 | -26.3% | 3,587 | -83.4% | 0.00% | -60.0% |
| Q1 2016 | $297,000 | – | 21,600 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |